No More Premature Ejaculation!

Experiencing orgasm and ejaculating is beyond a man's control, especially after a long abstinence. But when the woman does not even understand it all the time, there is a problem. Premature ejaculation (PE) represents a "persistent or recurrent onset of ejaculation with minimal sexual stimulation before, on, or shortly after penetration" and, of course, this is not the man's will.

PE is more than a sexual issue; it is a psychological condition, inducing distress and dissatisfaction in both man and woman. Recent investigations suggested that PE could be linked to an impairment in serotonergic 5-hydroxytrptamine (5-HT) neurotransmission.

That's why new PE therapies target the 5-HT system. A recent trial made by Francisco Giuliano from Garches Frances investigated the efficacy of a new PE drug, dapoxetine. Dapoxetine hydrochloride is a short-lived selective serotonin reuptake inhibitor (SSRI) targeting specifically the PE condition.

Other most available SSRIs like fluoxetine, sertraline and paroxetine increase ejaculatory latency time, but their effect is felt in several hours, while dapoxetine's maximal effect occurs in just 1 hour.

50 % of the drug is eliminated after 1.2 hours and after 24 hours only 5% of it is still found in the cells, making it more effective and safer.

The two-placebo trial was made on over 2600 male subjects, and dapoxetine, 30 or 60 mg, was taken 1-3 hours before the sexual intercourse and the volunteers' average age was 40.

65 % of the subjects had lifelong PE and 35% had PE that emerged after a time of normal sexual function. Data of intravaginal ejaculatory latency time (IELT), determined by stopwatch during intercourse, was gathered.

The duration of the sexual intercourse appeared linked to the dapoxetine dose: 0.9 - 1.75 minutes for placebo, 0.92 - 2.78 minutes for 30 mg of dapoxetine and 0.91 - 3.32 minutes for 60 mg of dapoxetine. The drug worked on the first dose, but also subsequent ones and the effect persisted during the 12-week trial.

Dapoxetine's secondary effects were weak: just mild nausea (8.7 % for the 30 mg dose and 20.1 % for the 60 mg dose) and headache (5.9% for the 30 mg dose and 6.8% for the 60 mg dose). Discontinuation induced by adverse effects was of 4 % for 30 mg dose and 10 % for the 60 mg dose.